| Investor relations information | 19 April 2010 |
Due to the Icelandic volcanic eruptions and subsequent flight cancellations, Galapagos will not be able to present results from its first-in-human trial for the cancer metastasis candidate drug, GLPG0187, at the American Association of Cancer Research (AACR) Annual Meeting being held this week in Washington, DC, USA.
About GLPG0187
GLPG0187, an integrin receptor antagonist (IRA), blocks five integrin receptors known to be present in many metastatic cancers, affording a unique anti-integrin profile. In animal studies, oral administration of GLPG0187 as a single agent has been shown to inhibit multiple processes involved in the spread and growth of metastatic tumors. The candidate drug has shown good safety and a promising biomarker profile in healthy volunteers. Based on these results, Galapagos plans to initiate a second Phase I trial including cancer patients later this year.
More information about the GLPG0187 program is online at http://www.glpg.com/pharmaceuticals/cancer_metastasis.htm
Or contact:
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240